Drug major Lupin on Thursday said it has received approval from the US health regulator to market generic fenofibrate tablets, used to treat high cholesterol, in the American market. The company has received final approval from the US Food and Drug Administration (USFDA) to market generic version of Teva's Fenofibrate tablets in strengths of 54mg and 160mg, Lupin said in a statement. The Mumbai-based company's US unit, Lupin Pharmaceuticals Inc would commence promoting the product shortly in the US, it added.
According to IMS MAT June data, fenofibrate tablets in strengths of 54 mg and 160 mg had US sales of USD 156 million. Lupin has close to 20 percent market share of the overall US Fenofibrate market. The drug firm now has a total of 81 products in the US market.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
